Pharma CEO says U.S. manufacturing capacity is 'limited' in event of coronavirus vaccine, treatment


Dr. Leonard Schleifer, the CEO of pharmaceutical company Regeneron, is optimistic that there will eventually be a breakthrough when it comes to combating the disease, whether that comes in the form of a drug or a vaccine. But there will still be obstacles, he told CNN's Jack Tapper on Sunday's State of the Union.
Regeneron is developing a coronavirus treatment. If and when a vaccine or treatment hits the market, there's still the question of how people will be able to access it, considering demand will be high, but Schleifer isn't too concerned about distribution — he thinks whatever is available will be at pharmacies and doctors' offices. Instead, he's more worried about the United States' manufacturing capacity, which he described as "limited."
Schleifer believes the one thing that's become clear throughout the pandemic is that the country needs more manufacturing capacity in place, generally speaking, so that if another novel virus rolls around in the future, the U.S. is in a better position to help everyone. Tim O'Donnell
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Today's political cartoons - April 17, 2025
Cartoons Thursday's cartoons - Harvard University, small businesses, and more
By The Week US
-
Fake AI job seekers are flooding U.S. companies
In the Spotlight It's getting harder for hiring managers to screen out bogus AI-generated applicants
By Theara Coleman, The Week US
-
The sneaky rise of whooping cough
Under the Radar The measles outbreak isn't the only one to worry about
By Theara Coleman, The Week US
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
By Peter Weber, The Week US
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
By Peter Weber, The Week US
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
By Peter Weber, The Week US
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
By Peter Weber, The Week US
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US